

1 **Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants**
2 **in the United States: A Prospective Observational Study**

3
4 **Authors:**

5
6 (1) Adam S. Luring, MD, PhD*

7 Departments of Internal Medicine and Microbiology and Immunology, University of Michigan,
8 Ann Arbor, Michigan

9 (2) Mark W. Tenforde, MD, PhD*

10 CDC COVID-19 Response Team, Atlanta, Georgia

11 (3) James D. Chappell, MD, PhD*

12 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee

13 (4) Manjusha Gaglani, MBBS

14 Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas

15 (5) Adit A. Ginde, MD, MPH

16 Department of Emergency Medicine, University of Colorado School of Medicine, Aurora,
17 Colorado

18 (6) Tresa McNeal, MD

19 Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas

20 (7) Shekhar Ghamande, MD

21 Baylor Scott and White Health, Texas A&M University College of Medicine, Temple, Texas

22 (8) David J. Douin, MD

23 Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado

24 (9) H. Keipp Talbot, MD, MPH

25 Departments of Medicine and Health Policy, Vanderbilt University Medical Center, Nashville,
26 Tennessee

27 (10) Jonathan D. Casey, MD, MSci

28 Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

29 (11) Nicholas M. Mohr, MD, MS

30 Department of Emergency Medicine, University of Iowa, Iowa City, Iowa

31 (12) Anne Zepeski, PharmD

32 Department of Emergency Medicine, University of Iowa, Iowa City, Iowa

33 (13) Nathan I. Shapiro, MD, MPH

34 Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston,
35 Massachusetts

36 (14) Kevin W. Gibbs, MD

37 Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina

38 (15) D. Clark Files, MD

39 Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina

40 (16) David N. Hager, MD, PhD

41 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

42 (17) Arber Shehu, MD

43 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

44 (18) Matthew E. Prekker, MD, MPH

45 Department of Emergency Medicine and Medicine, Hennepin County Medical Center,
46 Minneapolis, Minnesota

47 (19) Heidi L. Erickson, MD

48 Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota

- 49 (20) Matthew C. Exline, MD, MPH
50 Department of Medicine, The Ohio State University, Columbus, Ohio
- 51 (21) Michelle N. Gong, MD
52 Department of Medicine, Montefiore Health System, Albert Einstein College of Medicine, Bronx,
53 New York
- 54 (22) Amira Mohamed, MD
55 Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine,
56 Bronx, New York
- 57 (23) Nicholas J. Johnson, MD
58 Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep
59 Medicine, University of Washington, Seattle, Washington
- 60 (24) Vasisht Srinivasan, MD
61 Department of Emergency Medicine, University of Washington, Seattle, Washington
- 62 (25) Jay S. Steingrub, MD
63 Department of Medicine, Baystate Medical Center, Springfield, Massachusetts
- 64 (26) Ithan D. Peltan, MD, MSc
65 Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah,
66 Salt Lake City, Utah
- 67 (27) Samuel M. Brown, MD, MS
68 Department of Medicine, Intermountain Medical Center, Murray, Utah and University of Utah,
69 Salt Lake City, Utah
- 70 (28) Emily T. Martin, PhD
71 School of Public Health, University of Michigan, Ann Arbor, Michigan
- 72 (29) Arnold S. Monto, MD
73 School of Public Health, University of Michigan, Ann Arbor, Michigan
- 74 (30) Akram Khan, MD
75 Department of Medicine, Oregon Health and Sciences University, Portland, Oregon
- 76 (31) Catherine L. Hough, MD
77 Department of Medicine, Oregon Health and Sciences University, Portland, Oregon
- 78 (32) Laurence W. Busse, MD
79 Department of Medicine, Emory University, Atlanta, Georgia
- 80 (33) Caitlin C. ten Lohuis, ACNP-BC
81 Emory Critical Care Center, Emory Healthcare, Atlanta, Georgia
- 82 (34) Abhijit Duggal, MD
83 Department of Medicine, Cleveland Clinic, Cleveland, Ohio
- 84 (35) Jennifer G. Wilson, MD
85 Department of Emergency Medicine, Stanford University School of Medicine, Stanford,
86 California
- 87 (36) Alexandra June Gordon, MD
88 Department of Emergency Medicine, Stanford University School of Medicine, Stanford,
89 California
- 90 (37) Nida Qadir, MD
91 Department of Medicine, University of California-Los Angeles, Los Angeles, California
- 92 (38) Steven Y. Chang, MD, PhD
93 Department of Medicine, University of California-Los Angeles, Los Angeles, California
- 94 (39) Christopher Mallow, MD, MHS
95 Department of Medicine, University of Miami, Miami, Florida
- 96 (40) Carolina Rivas

97 Department of Medicine, University of Miami, Miami, Florida
98 (41) Hilary M. Babcock, MD, MPH
99 Department of Medicine, Washington University, St. Louis, Missouri
100 (42) Jennie H. Kwon, DO, MS
101 Department of Medicine, Washington University, St. Louis, Missouri
102 (43) Natasha Halasa, MD, MPH
103 Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
104 (44) Carlos G. Grijalva, MD, MPH
105 Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
106 (45) Todd W. Rice, MD, MSc
107 Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
108 (46) William B. Stubblefield, MD, MPH
109 Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
110 (47) Adrienne Baughman
111 Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
112 (48) Kelsey N. Womack, PhD
113 Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical
114 Center, Nashville, Tennessee
115 (49) Jillian P. Rhoads, PhD
116 Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical
117 Center, Nashville, Tennessee
118 (50) Christopher J. Lindsell, PhD
119 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
120 (51) Kimberly W. Hart, MA
121 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
122 (52) Yuwei Zhu, MD, MS
123 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
124 (53) Katherine Adams, MPH
125 CDC COVID-19 Response Team, Atlanta, Georgia
126 (54) Stephanie J. Schrag, Dphil
127 CDC COVID-19 Response Team, Atlanta, Georgia
128 (55) Samantha M. Olson, MPH
129 CDC COVID-19 Response Team, Atlanta, Georgia
130 (56) Miwako Kobayashi, MD
131 CDC COVID-19 Response Team, Atlanta, Georgia
132 (57) Jennifer R. Verani, MD
133 CDC COVID-19 Response Team, Atlanta, Georgia
134 (58) Manish M. Patel, MD
135 CDC COVID-19 Response Team, Atlanta, Georgia
136 (59) Wesley H. Self, MD, MPH
137 Department of Emergency Medicine and Vanderbilt Institute for Clinical and Translational
138 Research, Vanderbilt University Medical Center, Nashville, Tennessee
139 For the Influenza and Other Viruses in the Acutely Ill (IVY) Network**

140
141 * Dr. Luring, Dr. Tenforde, and Dr. Chappell contributed equally to this work as lead authors.
142 **A full list of investigators and collaborators in the Influenza and other Viruses in the Acutely Ill (IVY)
143 Network is available in the Supplementary Appendix.
144

145 **Corresponding Author:**

146 Wesley H. Self, MD, MPH; Vanderbilt University Medical Center; email: wesley.self@vumc.org; mail:
147 1313 21st Avenue South, 312 Oxford House, Nashville TN 37232, USA. ORCID: [0000-0002-9300-3045](https://orcid.org/0000-0002-9300-3045).

148

149 **Disclaimer:**

150 The findings and conclusions in this report are those of the authors and do not necessarily represent the
151 views of the Centers for Disease Control and Prevention/the Agency for Toxic Substances and Disease
152 Registry.

153

154 **Key Words:**

155 COVID-19; SARS-CoV-2; vaccine effectiveness; attenuation; mRNA vaccines; delta variant; omicron
156 variant

157

158 **Word Counts:**

159 Abstract: 390

160 Main Text: 4385

161 **ABSTRACT**

162 **Objectives:** To characterize the clinical severity of COVID-19 caused by Omicron, Delta, and Alpha SARS-
163 CoV-2 variants among hospitalized adults and to compare the effectiveness of mRNA COVID-19 vaccines
164 to prevent hospitalizations caused by each variant.

165 **Design:** A case-control study of 11,690 hospitalized adults.

166 **Setting:** Twenty-one hospitals across the United States.

167 **Participants:** This study included 5728 cases hospitalized with COVID-19 and 5962 controls hospitalized
168 without COVID-19. Cases were classified into SARS-CoV-2 variant groups based on viral whole genome
169 sequencing, and if sequencing did not reveal a lineage, by the predominant circulating variant at the
170 time of hospital admission: Alpha (March 11 to July 3, 2021), Delta (July 4 to December 25, 2021), and
171 Omicron (December 26, 2021 to January 14, 2022).

172 **Main Outcome Measures:** Vaccine effectiveness was calculated using a test-negative design for COVID-
173 19 mRNA vaccines to prevent COVID-19 hospitalizations by each variant (Alpha, Delta, Omicron). Among
174 hospitalized patients with COVID-19, disease severity on the WHO Clinical Progression Ordinal Scale was
175 compared among variants using proportional odds regression.

176 **Results:** Vaccine effectiveness of the mRNA vaccines to prevent COVID-19-associated hospitalizations
177 included: 85% (95% CI: 82 to 88%) for 2 vaccine doses against Alpha; 85% (95% CI: 83 to 87%) for 2 doses
178 against Delta; 94% (95% CI: 92 to 95%) for 3 doses against Delta; 65% (95% CI: 51 to 75%) for 2 doses
179 against Omicron; and 86% (95% CI: 77 to 91%) for 3 doses against Omicron. Among hospitalized
180 unvaccinated COVID-19 patients, severity on the WHO Clinical Progression Scale was higher for Delta
181 than Alpha (adjusted proportional odds ratio [aPOR] 1.28, 95% CI: 1.11 to 1.46), and lower for Omicron
182 than Delta (aPOR 0.61, 95% CI: 0.49 to 0.77). Compared to unvaccinated cases, severity was lower for

183 vaccinated cases for each variant, including Alpha (aPOR 0.33, 95% CI: 0.23 to 0.49), Delta (aPOR 0.44,
184 95% CI: 0.37 to 0.51), and Omicron (aPOR 0.61, 95% CI: 0.44 to 0.85).

185 **Conclusions:** mRNA vaccines were highly effective in preventing COVID-19-associated hospitalizations
186 from Alpha, Delta, and Omicron variants, but three vaccine doses were required to achieve protection
187 against Omicron similar to the protection that two doses provided against Delta and Alpha. Among
188 adults hospitalized with COVID-19, Omicron caused less severe disease than Delta, but still resulted in
189 substantial morbidity and mortality. Vaccinated patients hospitalized with COVID-19 had significantly
190 lower disease severity than unvaccinated patients for all the variants.

191 **INTRODUCTION**

192 The coronavirus disease 2019 (COVID-19) pandemic has been defined by both the distribution of highly
193 effective vaccines and the serial emergence of new severe acute respiratory syndrome coronavirus-2
194 (SARS-CoV-2) genetic variants [1]. Variants of concern are new genetic versions of the virus with
195 increased transmissibility, a change in virulence or disease presentation, or a decrease in effectiveness
196 of mitigation measures, available vaccines, or therapeutics [2]. There are now five WHO designated
197 SARS-CoV-2 variants of concern: Alpha (B.1.1.7 and descendant lineages), Beta (B.1.351), Gamma (P.1),
198 Delta (B.1.617.2 and AY lineages), and Omicron (B.1.1.529 and BA lineages).

199 First identified in Spring 2021, the highly contagious Delta variant rapidly replaced other SARS-
200 CoV-2 variants and achieved global dominance by Summer 2021 [3]. Early studies suggested potential
201 for increased risk of hospitalization for Delta-infected individuals compared to prior variants [4–6]. The
202 highly divergent Omicron variant was identified in mid-November 2021 and quickly became the
203 dominant variant in much of Europe and North America by late-December 2021 [7]. The overall risk of
204 hospitalization among those infected with the Omicron variant appears to be lower than those infected
205 with the Delta variant [8]. However, hospitalizations for Omicron infection do occur and disease severity
206 and risk for progression to critical illness remain incompletely understood for this variant.

207 Understanding the epidemiology SARS-CoV-2 variants and the effectiveness of existing vaccines
208 against them are essential to guide vaccination policies and development of new vaccines. Early studies
209 suggested reduced vaccine effectiveness against infection and hospitalization for Omicron compared to
210 earlier variants [9–11]. In most cases, estimates of vaccine effectiveness against the Omicron variant
211 were based on cases that occurred during time periods in which the Omicron variant exceeded 50% in
212 genomic surveillance. While efficient, these approaches have the potential for variant misclassification
213 and inaccurate vaccine effectiveness estimates. Furthermore, little is known about the effectiveness of

214 vaccines for the prevention of the most severe manifestations of COVID-19, including respiratory failure
215 and death, for patients with Omicron infection.

216 Using observational study designs, the Influenza and Other Viruses in the Acutely Ill (IVY)
217 Network in collaboration with the United States Centers for Disease Control and Prevention (CDC) is
218 studying the effectiveness of COVID-19 vaccines against severe disease (Table S1) [12–15]. Here, we
219 compare the clinical severity of COVID-19 caused by the SARS-CoV-2 Alpha, Delta and Omicron variants
220 among hospitalized adults in the United States and the effectiveness of mRNA COVID-19 vaccines
221 against each of these variants.

222

223 **METHODS**

224 **Design and Setting**

225 We conducted a prospective observational study at 21 hospitals in the United States, with enrollment of
226 adults hospitalized with laboratory-confirmed COVID-19 and concurrent controls without COVID-19. A
227 test-negative design was utilized to assess vaccine effectiveness [16]. This program was conducted by
228 the IVY Network, which is a group consisting of geographically dispersed academic medical centers in
229 the United States, coordinated from Vanderbilt University Medical Center, and funded by CDC (Table
230 S1). Participants enrolled in the IVY program with hospital admission dates between March 11, 2021,
231 and January 14, 2022 were included in this analysis. This program was approved as a public health
232 surveillance activity with waiver of informed consent by CDC and all participating sites.

233 This analysis compared the Alpha, Delta, and Omicron SARS-CoV-2 variants in three ways: (1)
234 vaccine effectiveness of the COVID-19 mRNA vaccines to prevent hospitalizations due to each variant;
235 (2) disease severity among unvaccinated and vaccinated patients hospitalized with each variant; and (3)

236 vaccine effectiveness of the COVID-19 mRNA vaccines to prevent disease progression to invasive
237 mechanical ventilation or death after hospitalization with each variant.

238

239 **Participants**

240 Sites prospectively screened hospitalized adults ≥ 18 years old for potential eligibility through daily
241 review of hospital admission logs and electronic medical records. COVID-19 cases included those
242 hospitalized with a clinical syndrome consistent with acute COVID-19 (≥ 1 of the following: fever; cough;
243 shortness of breath; loss of taste; loss of smell; use of respiratory support for the acute illness; or new
244 pulmonary findings on chest imaging consistent with pneumonia) and a positive molecular or antigen
245 test for SARS-CoV-2 within 10 days of symptom onset. As described below, COVID-19 case patients were
246 subclassified based on SARS-CoV-2 variant. Additionally, two control groups were enrolled: 1) “test-
247 negative” controls were adults hospitalized with signs or symptoms consistent with acute COVID-19 who
248 tested negative for SARS-CoV-2; and 2) “syndrome-negative” controls were adults hospitalized without
249 signs or symptoms consistent with acute COVID-19 and who tested negative for SARS-CoV-2 [17].
250 Controls were selected from lists of eligible participants hospitalized within 2 weeks of enrollment of
251 COVID-19 cases. Sites attempted to capture all COVID-19 cases admitted to the hospital during the
252 surveillance period and targeted a case: control ratio of approximately 1:1. Cases and controls were not
253 individually matched. Respiratory samples from participants were tested for SARS-CoV-2 both locally in
254 clinical laboratories and centrally at a research laboratory (see Laboratory Analysis section). Cases tested
255 positive for SARS-CoV-2 at a local laboratory, the central laboratory, or both, while controls tested
256 negative for SARS-CoV-2 by all testing. Additional details about eligibility criteria and enrollment
257 practices are described in Supplementary Appendix B [13,14].

258

259 **Data Collection**

260 Trained personnel collected data on demographics, medical conditions, COVID-19 vaccination, and
261 hospital course through participant (or proxy) interviews and standardized medical record review.
262 Details of COVID-19 vaccination, including dates and location of vaccination, vaccine product, and lot
263 number, were collected through a systematic process that included participant (or proxy) interview and
264 source verification by vaccination card, hospital records, state vaccine registries, and vaccine records
265 requested from clinics and pharmacies [13,14].

266

267 **Vaccination Status**

268 Vaccine doses were classified as administered if source documentation of the dose was identified or if
269 the participant/proxy reported a vaccine dose with a complete and plausible date and location. This
270 analysis focused on COVID-19 mRNA vaccines authorized or approved for use in the United States,
271 including BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna). Participants were classified based on
272 the number of mRNA vaccine doses received before illness onset: 0 doses (unvaccinated); 1 dose ≥ 14
273 days before illness (partially vaccinated); 2 doses ≥ 14 days before illness (fully vaccinated); or 3 doses ≥ 7
274 days before illness (boosted if immunocompetent, or with primary 3-dose series completed if
275 immunocompromised). In the primary analysis, vaccine effectiveness was calculated for 2 vaccine doses
276 for participants enrolled throughout the surveillance period and for 3 vaccine doses for participants
277 enrolled after third doses were authorized in the United States [18,19]. In a secondary analysis, vaccine
278 effectiveness was calculated for partial vaccination. Participants were excluded from this analysis if they
279 received a COVID-19 vaccine other than an mRNA vaccine (e.g., the Ad26.COV2 vaccine from Janssen),
280 more than 3 vaccine doses, or a third vaccine dose before they were authorized in the United States
281 [18–20].

282 **Laboratory Analysis**

283 Upper respiratory specimens (nasal swabs or saliva) were collected from participants, frozen, and
284 shipped to Vanderbilt University Medical Center (Nashville, Tennessee), where they underwent reverse-
285 transcription quantitative polymerase chain reaction (RT-qPCR) for detection of two SARS-CoV-2
286 nucleocapsid gene targets (N1 and N2) [21]. Respiratory specimens positive for SARS-CoV-2 were
287 shipped to the University of Michigan (Ann Arbor, Michigan) for viral whole-genome sequencing using
288 the ARTIC Network protocol on an Oxford Nanopore Technologies GridION instrument [22]. SARS-CoV-2
289 lineages were assigned using Pangolin [23]. The WHO variant assignment was as follows: Alpha (B.1.1.7),
290 Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2 and AY lineages), Omicron (B.1.1.529 or BA lineages).

291

292 **COVID-19 disease severity**

293 We classified COVID-19 disease severity based on the highest severity state reached during the index
294 COVID-19 hospital admission using a modified version of the WHO COVID-19 Clinical Progression Scale
295 (Table S2) [13,24]. In this analysis of hospitalized patients, the scale levels included: hospitalized without
296 supplemental oxygen (level 4), hospitalized with standard supplemental oxygen (level 5), hospitalized
297 with high flow nasal cannula or non-invasive ventilation (level 6), hospitalized with invasive mechanical
298 ventilation (level 7), hospitalized with mechanical ventilation and additional organ support (e.g., ECMO,
299 vasopressors; level 8), and death (level 9). In addition to evaluating the full scale (levels 4-9) as an
300 ordinal outcome, we also dichotomized the scale at level 7 to facilitate comparison between patients
301 who experienced death or invasive mechanical ventilation (levels 7-9) vs those who did not experience
302 death or invasive mechanical ventilation (levels 4-6).

303

304 **Statistical Analysis**

305 COVID-19 cases were classified into Alpha, Delta, and Omicron categories using sequencing information
306 for cases with lineages identified and by the predominant circulating variant at the time of hospital
307 admission for those without a lineage identified. Periods of predominant circulation for Alpha, Delta and
308 Omicron were defined based on time windows when each variant was identified in >50% of cases
309 successfully sequenced in the study—Alpha period: March 11 – July 3, 2021; Delta period: July 4 –
310 December 25, 2021; and Omicron period: December 26, 2021 – January 14, 2022. For analyses
311 evaluating vaccine effectiveness to prevent hospitalization, evaluating cases and controls enrolled
312 during the same time period was important to maintain accuracy of vaccine effectiveness estimates. For
313 analyses evaluating vaccine effectiveness against hospitalization, cases and controls in each period
314 (Alpha, Delta, and Omicron) were compared; cases were excluded from these analyses if they had a
315 lineage identified by sequencing that was discordant with the period (for example, a Delta lineage
316 identified in the Omicron period). For severity analyses, only cases were analyzed and maintaining a
317 temporal relationship with a control group was not necessary; therefore, all cases with sequencing-
318 confirmed Alpha, Delta, or Omicron lineage were analyzed regardless of admission date; in these
319 analyses, variant group was classified by sequencing confirmation of Alpha, Delta or Omicron lineage,
320 and then for other cases, by period.

321 Vaccine effectiveness of COVID-19 mRNA vaccines (BNT162b2 or mRNA-1273) to prevent
322 hospitalization for COVID-19 was calculated using a test-negative design, in which the odds of
323 antecedent vaccination were compared between cases and controls. Participants in the test-negative
324 and syndrome-negative control groups were pooled based on analyses demonstrating highly similar
325 vaccine coverage in the two control groups and nearly identical vaccine effectiveness estimates when
326 either control group was used individually [14]. A multivariable unconditional logistic regression model
327 was constructed with case-control status as the dependent variable, vaccination status (vaccinated vs.

328 unvaccinated) as the primary independent variable and the following covariables selected *a priori* as
329 potential confounders: calendar date of admission in biweekly intervals, US Department of Health and
330 Human Services region (10 regions), age, sex, and self-reported race and Hispanic ethnicity. Post-hoc,
331 the following variables were considered for potential inclusion as covariates but none of them changed
332 the adjusted odds ratio (aOR) by more than 5% and were not included in the final analysis: number of
333 comorbidities, smoking status, living in a long-term care facility before hospital admission and working in
334 a healthcare setting. Vaccine effectiveness to prevent COVID-19 hospitalization [VE(hospitalization)] was
335 calculated with the adjusted odds ratio (aOR) from this model as: $VE(\text{hospitalization}) = (1 - aOR) \times 100$.
336 Using this method, vaccine effectiveness against COVID-19 hospitalization as calculated separately for
337 the Alpha, Delta, and Omicron. Vaccine effectiveness for two vaccine doses was calculated for each
338 period, and for three vaccine doses for the Delta and Omicron periods. Within each period, vaccine
339 effectiveness was also calculated for subgroups defined by: immunocompromised status [14]; age group
340 (18-64 years; ≥ 65 years); burden of chronic medical conditions (0; ≥ 1 medical conditions); vaccine
341 product (BNT162b2; mRNA-1273); and for two vaccine doses recipients, the time between the second
342 vaccine dose and symptom onset (14-150 days; >150 days). This threshold of 150 days was selected
343 based on the recommendation for a third (booster) dose of mRNA vaccine after 5 months for
344 immunocompetent adults [23]. Results for subgroup analyses that had >150 cases and controls were
345 reported.

346 COVID-19 severity by variant and by vaccination status was displayed by plotting the highest
347 severity level on the modified WHO Clinical Progression Scale attained for each case. COVID-19 severity
348 was compared among unvaccinated cases by variant (Alpha, Delta, Omicron) and between unvaccinated
349 and vaccinated cases within each group. In these analyses of severity, patients vaccinated with either 2
350 or 3 doses of an mRNA vaccine were considered fully vaccinated. These calculations were performed
351 using a multivariable proportional odds regression model with WHO ordinal scale as the dependent

352 variable (levels 4-9), variant group (Alpha, Delta, Omicron) or vaccination status (unvaccinated,
353 vaccinated) as the primary independent variable and the following covariables: age, sex, race and
354 Hispanic ethnicity, and number of underlying medical conditions (0, 1, 2, 3, or ≥ 4 classes of chronic
355 conditions). An adjusted proportional odds ratio (aPOR) >1.0 from these models indicated more severe
356 disease for the later variant than a comparator earlier variant, for example Delta compared with Alpha,
357 and Omicron compared with Delta.

358 Next, the vaccine effectiveness was calculated for mRNA vaccines to prevent disease
359 progression to invasive mechanical ventilation or death among adults hospitalized with COVID-19. A
360 multivariable logistic regression model was constructed with the composite of invasive mechanical
361 ventilation or death as the dependent variable, vaccination status (vaccinated with 2 or 3 doses vs
362 unvaccinated) as the primary independent variable and the same covariables as included in the severity
363 proportional odds model. Vaccine effectiveness to prevent in-hospital disease progression was
364 calculated as: $VE(\text{progression}) = (1 - aOR) \times 100$. Using this method, vaccine effectiveness against
365 disease progression was calculated separately for the Alpha, Delta, and Omicron groups.

366 Results were considered statistically significant if 95% confidence intervals for odds ratios did
367 not include the null (OR=1.0) or two-sided p-values were <0.05 . Missing values were not imputed;
368 results were presented with denominators to indicate sample size in each analysis and models included
369 participants with complete data for all variables in the model. Statistical analyses were performed with
370 Stata Version 16 (College Station, TX) and SAS 9.4 (Cary, NC).

371

372 **RESULTS**

373 **Participants and SARS-CoV-2 Variants**

374 Between March 11, 2021 and January 14, 2022, 14,128 patients were enrolled across 21 hospitals; 2,438
375 patients were excluded from the primary analyses, most commonly for receiving >1 mRNA vaccine dose
376 but not classifying into the two-dose or three-dose vaccine recipient categories (n=933) or for receiving
377 a non-mRNA vaccine (n=682) (Figure S1). The population for analysis included 11,690 patients, including
378 5,728 COVID-19 cases and 5,962 controls.

379 SARS-CoV-2 sequencing results were obtained for 2,599/5,728 (45%) cases in the analytical
380 population. Among cases with sequencing completed, during the Alpha period 242/421 (57%) cases had
381 Alpha identified by sequencing, during the Delta period 1,867/1,930 (97%) cases had Delta identified by
382 sequencing, and during the Omicron period 190/248 (77%) cases had Omicron identified by sequencing
383 (Figure 1; Table S3).

384

385 **Vaccine Effectiveness to Prevent COVID-19 Hospitalizations**

386 After excluding 146/5,728 (3%) cases from the vaccine effectiveness against hospitalization analysis who
387 had sequence-confirmed lineage discordant from the variant-predominant period (e.g., cases with
388 sequencing-confirmed Delta variant during the Alpha or Omicron period), 5,582 cases and 5,962 controls
389 were included in this part of the analysis. Cases included 1,072 from the Alpha period, 3,951 from the
390 Delta period, and 559 from the Omicron period. Compared to cases in the Alpha and Delta period, cases
391 in the Omicron group tended to be older, have more underlying medical conditions, and more likely to
392 have ≥ 1 prior hospitalization in the past year (Table 1, Table S4). Consistent with increasing vaccine
393 coverage in the United States population over time, a greater proportion of cases were vaccinated (2 or
394 3 doses of an mRNA vaccine) during the Omicron period (291/559, 52%) than the Alpha (119/1072, 11%)
395 and Delta (1080/3951, 27%) periods.

396 Vaccine effectiveness for two doses of mRNA vaccine to prevent COVID-19 hospitalization was
397 85% (95% CI: 82 to 88%) in the Alpha period, 85% (95% CI: 83 to 87%) in the Delta period, and 65% (95%
398 CI: 51 to 75%) in the Omicron period (Figure 2). Vaccine effectiveness for three mRNA vaccine doses in
399 the Omicron period was 86% (95% CI: 77 to 91%), which was similar to the effectiveness of two doses
400 during the Alpha and Delta periods. Within the Delta period, vaccine effectiveness for two vaccine doses
401 was lower when the second vaccine dose was >150 days before illness onset (81%; 95% CI: 78 to 84%)
402 than 14-150 days (88%; 95% CI: 86 to 90%). Within the Delta period, vaccine effectiveness of three
403 vaccine doses (94%; 95% CI: 92 to 95%) was higher than two doses, with high vaccine effectiveness
404 observed after a third dose in both immunocompetent (97%; 95% CI: 95 to 98%) and
405 immunocompromised (87%; 95% CI: 78 to 92%) patients. Within each period, vaccine effectiveness was
406 lower for immunocompromised patients compared to immunocompetent patients and lower for the
407 BNT162b2 vaccine than the mRNA-1273 vaccine. Vaccine effectiveness results for partial vaccination
408 (either 1 dose of an mRNA vaccine or 2 doses with the second dose received <14 days before illness
409 onset) are described in Supplementary Appendix C.

410

411 **COVID-19 Disease Severity**

412 The severity analysis included data collected through January 31, 2022. Of 5,728 case patients in the
413 study, 5,413 (95%) had complete clinical outcomes data and were included in the severity analysis,
414 including 1,060 in the Alpha group, 3,788 in the Delta group, and 565 in the Omicron group. Overall,
415 including both vaccinated and unvaccinated patients, 582/5,413 (11%) COVID-19 patients died within 28
416 days during the index hospitalization, including 81/1,060 (8%) in the Alpha group, 461/3,788 (12%) in
417 the Delta group, and 40/565 (7%) in the Omicron group.

418 Among unvaccinated cases, COVID-19 severity on the WHO Clinical Progression Scale was
419 highest for the Delta group (Delta vs Alpha aPOR 1.28, 95% CI: 1.11 to 1.46) and lowest for the Omicron
420 group (Omicron vs Alpha aPOR 0.79, 95% CI: 0.62 to 1.01; Omicron vs Delta aPOR 0.61, 95% CI: 0.49 to
421 0.77) (Figure 3). Among unvaccinated cases, in-hospital death occurred in 76/944 (8%) in the Alpha
422 group, 323/2,743 (12%) in the Delta group, and 25/272 (9%) in the Omicron group (Table 2). COVID-19
423 severity on the WHO Clinical Progression Scale was substantially lower for vaccinated cases than
424 unvaccinated cases in each variant group, including Alpha (aPOR: 0.33; 95% CI: 0.23-0.49), Delta (aPOR
425 0.44; 95% CI: 0.37 to 0.51), and Omicron (aPOR: 0.61; 95% CI: 0.44 to 0.85).

426 Across all variants, vaccinated COVID-19 patients who died tended to be old and had multiple
427 medical conditions or immunocompromising conditions. Compared with the 424 unvaccinated COVID-19
428 patients who died, 158 vaccinated patients who died were older (median 72 vs 61 years; $p < 0.001$), more
429 likely to be immunocompromised (41% versus 13%; $p < 0.001$), had more categories of chronic medical
430 conditions (median 3 versus 2; $p < 0.001$), and had more prescribed medications prior to hospital
431 admission (median 10 versus 5; $p < 0.001$).

432

433 **Vaccine Effectiveness to Prevent COVID-19 Disease Progression after Hospitalization**

434 Among patients hospitalized with COVID-19, vaccine effectiveness of mRNA vaccination (2 or 3 doses) to
435 prevent progression to invasive mechanical ventilation or death was 76% (95% CI: 53 to 88%) for Alpha,
436 44% (95% CI: 32 to 54%) for Delta, and 46% (95% CI: 12 to 67%) for Omicron. Vaccine effectiveness to
437 prevent disease progression was observed for immunocompetent patients for all three variants, but not
438 observed for immunocompromised patients for Delta or Omicron (Figure 4).

439

440 **DISCUSSION**

441 **Principal Findings**

442 The predominant circulating SARS-CoV-2 variant in the United States changed from Alpha to Delta in July
443 2021 and then to Omicron in December 2021. Understanding the disease severity caused by each
444 variant and the effectiveness of available vaccines against them is essential for guiding vaccination
445 policies and directing future vaccine development. The mRNA COVID-19 vaccines that were authorized
446 for use in the United States in 2020 (BNT162b2 and mRNA-1273) were highly effective at preventing
447 hospitalizations for all three variants during the subsequent year. However, three doses of an mRNA
448 vaccine were necessary to achieve similar effectiveness against Omicron in the winter of 2021-2022 as
449 two doses achieved for Alpha and Delta variants earlier in the year. Furthermore, while COVID-19
450 hospitalizations did occur among vaccinated patients, vaccination was associated with reduced risk of
451 progression to invasive mechanical ventilation or death for all three variants.

452 Among unvaccinated hospitalized adults with COVID-19, Delta variant caused the most severe
453 disease, followed by Alpha, and then Omicron. Among hospitalized unvaccinated patients, COVID-19
454 caused by Omicron was about 79% as severe as Alpha and 61% as severe as Delta. However, the
455 Omicron variant did cause a substantial amount of critical illness and death, with 15% of all patients
456 hospitalized with Omicron (vaccinated and unvaccinated) progressing to invasive mechanical ventilation
457 and 7% dying in the hospital.

458

459 **Strengths and Limitations**

460 This work has several strengths. The vaccine effectiveness analyses applied a test-negative design to a
461 large, hospitalized population of patients with symptomatic, laboratory-confirmed COVID-19 and

462 concurrent controls, which enabled control for healthcare seeking behavior, robust subgroup analyses,
463 and evaluation of outcomes beyond hospital admission, including level of respiratory support and
464 mortality. Ascertainment of vaccination status was robust, with trained personnel conducting patient
465 interviews and searching multiple sources of vaccination records on a patient-by-patient basis.
466 Respiratory samples collected in the study underwent centralized RT-PCR testing and viral whole
467 genome sequencing, which enabled precise characterization of time periods dominated by different
468 variants.

469 The study also had limitations. First, use of hospitalized controls might lead to biased estimates
470 if control patients had different characteristics than people in the general community; however, vaccine
471 coverage in the control population within this study tracked closely with that in the adult population in
472 the United States [25], which lessens this potential concern. Second, this study only evaluated
473 hospitalized patients and thus does not inform vaccine effectiveness against mild COVID-19 or
474 differences in disease severity among SARS-CoV-2 variants in the outpatient setting. Third, the study
475 only evaluated mRNA vaccines and did not assess other types of COVID-19 vaccines. Fourth, the analyses
476 of in-hospital severity did not account for potential differences in clinical management during the Alpha,
477 Delta, and Omicron periods that may have impacted outcomes. Fifth, while the test negative design is
478 the preferred method for evaluating vaccine effectiveness with observational data [16], it has known
479 potential limitations, including collider bias [26,27]; the risk of collider bias was minimized in the current
480 study by evaluating only severely ill patients [16]. Sixth, sequencing did not identify a variant for some
481 cases, typically those with low viral loads in the respiratory sample that underwent testing. Variant
482 classification for cases without a sequencing-confirmed variant was based on the predominant
483 circulating variant at the time; variant misclassification was possible for these cases.

484

485 **Comparison with Other Studies**

486 Earlier studies from England [5] and Scotland [4] found an increased risk of hospital admission for Delta
487 variant compared to Alpha variant. More recent studies have suggested that persons diagnosed with
488 Omicron variant COVID-19 are less likely than those with Delta to be hospitalized [8]. This study adds
489 robust measurements of disease severity after hospital admission and demonstrates Delta variant
490 caused more severe disease than Alpha and Omicron variants, driven largely by higher rates of advanced
491 respiratory support.

492 Emerging vaccine effectiveness estimates globally suggest reduced effectiveness against
493 Omicron compared with prior variants [28–30], including an estimate of 70% vaccine effectiveness for
494 two doses of the BNT162b2 vaccine to prevent Omicron hospitalizations in South Africa in November-
495 December 2021 [9]. Using electronic health record data from sites across the United States, the VISION
496 Network recently estimated mRNA vaccine effectiveness against Omicron hospitalizations to be to 52%
497 for two vaccine doses with the second dose received within 180 days before illness onset, 38% for 2
498 doses received >180 days before illness onset, and 82% for 3 vaccine doses [11]. Prior studies largely
499 relied on estimating predominant circulating SARS-CoV-2 variants from external data. This study adds
500 vaccine effectiveness results against severe disease using sequence data from within the study and
501 demonstrates strong protection against Omicron for three mRNA vaccine doses in the first several
502 months after receipt of a third dose.

503

504 **Policy Implications**

505 These data indicate that Omicron-variant COVID-19 is a serious disease among those who are
506 hospitalized, and preventative measures are indicated. Vaccination with existing mRNA vaccine
507 formulations is an effective preventative measure against Omicron, both for the prevention of
508 hospitalization, and among those hospitalized, for the prevention of progression to critical illness and

509 death. COVID-19 deaths in vaccinated individuals do occur, including with the Omicron variant, mostly in
510 the elderly, the immunocompromised, or those with multiple medical comorbidities. These findings
511 support recent recommendations in the United States for third mRNA vaccine doses for both
512 immunocompetent [19] and immunocompromised [18] adults as a key approach to protecting
513 populations against the Omicron variant.

514 The serial emergence of new SARS-CoV-2 variants, including Delta and Omicron, has challenged
515 public health agencies to develop vaccine policies that counter the impact of waning immunity (the
516 decline in protection of vaccine doses over time against the same variant) and viral immune evasion
517 (new viral variants that are less susceptible to existing vaccines). Vaccine booster doses of the same
518 vaccine formulation used in the primary vaccine series are designed to counter waning immunity.
519 Significant viral immune evasion would require new vaccine formulations targeting new variants to
520 maintain protection. Boosters were implemented in several countries in response to COVID-19 spikes
521 with emergence of the Delta variant. This study suggests that these booster doses were largely effective
522 in preventing severe disease with both Delta and the subsequent Omicron variant. As the COVID-19
523 pandemic continues to evolve, routine vaccine effectiveness monitoring, especially against severe
524 disease, and surveillance programs to identify viral variants will be essential to inform decisions about
525 booster vaccine policies and vaccine strain updates.

526

527 **Conclusions**

528 In this large study of hospitalized adults in the United States, mRNA vaccines provided strong protection
529 against COVID-19 hospitalization caused by the Alpha, Delta, and Omicron variants. Furthermore,
530 vaccination reduced the risk for COVID-19 progressing to critical illness or death for each of the variants.
531 While disease severity for patients hospitalized with COVID-19 was somewhat lower for Omicron than

532 the Alpha and Delta variants, patients hospitalized with Omicron-variant COVID-19 still had a substantial
533 risk for critical illness and death. These findings suggest that vaccination against COVID-19, including a
534 third dose of an mRNA vaccine, is critical for protecting populations against COVID-19-associated
535 morbidity and mortality.

536

537 **NOTES**

538 **Contributions:** Guarantors of this work include Dr. Self (protocol and data integrity), Dr. Tenforde
539 (statistical analysis), Dr. Luring (viral sequencing laboratory methods), and Dr. Chappell (RT-PCR
540 laboratory methods). Contributions of each author include the following. Responsibility for decision to
541 submit the manuscript: Self. Composed the initial manuscript draft: Luring, Tenforde, Chappell, Patel,
542 Self (the authors alone wrote the manuscript without outside assistance). Conceptualization of study
543 methods: Luring, Tenforde, Chappell, Talbot, Lindsell, Grijalva, Schrag, Kobayashi, Verani, Patel, Self.
544 Data Collection: Luring, Chappell, Gaglani, Ginde, McNeal, Ghamande, Douin, Talbot, Casey, Mohr,
545 Zepeski, Shapiro, Gibbs, Files, Hager, Shehu, Prekker, Erickson, Exline, Gong, Mohamed, Johnson,
546 Srinivasan, Steingrub, Peltan, Brown, Martin, Monto, Khan, Hough, Busse, ten Lohuis, Duggal, Wilson,
547 Gordon, Qadir, Chang, Mallow, Rivas, Babcock, Kwon, Halasa, Grijalva, Rice, Stubblefield, Baughman,
548 Womack, Rhoads, Self. Statistical analysis and data management: Tenforde, Lindsell, Hart, Zhu, Adams,
549 Olson. Funding acquisition: Self. Critical review of the manuscript for important intellectual content:
550 Luring, Tenforde, Chappell, Gaglani, Ginde, McNeal, Ghamande, Douin, Talbot, Casey, Mohr, Zepeski,
551 Shapiro, Gibbs, Files, Hager, Shehu, Prekker, Erickson, Exline, Gong, Mohamed, Johnson, Srinivasan,
552 Steingrub, Peltan, Brown, Martin, Monto, Khan, Hough, Busse, ten Lohuis, Duggal, Wilson, Gordon,
553 Qadir, Chang, Mallow, Rivas, Babcock, Kwon, Halasa, Grijalva, Rice, Stubblefield, Baughman, Womack,
554 Rhoads, Lindsell, Hart, Zhu, Adams, Schrag, Olson, Kobayashi, Verani, Patel, Self. The corresponding

555 author (Dr. Self) attests that all listed authors meet authorship criteria and that no others meeting the
556 criteria have been omitted.

557 **Funding:** Primary funding for this study was provided by the US Centers for Disease Control and
558 Prevention (award 75D30121F00002 to Dr. Self). Scientists from the US CDC participating in all aspects
559 of this study, including its design, analysis, interpretation of data, writing the report, and the decision to
560 submit the article for publication. The REDCap data tool used in this study was supported by a Clinical
561 and Translational Science Award (UL1 TR002243) from the National Center for Advancing Translational
562 Sciences, National Institutes of Health.

563 **Competing Interests:** All authors have completed the ICMJE uniform disclosure form at
564 www.icmje.org/coi_disclosure.pdf. The following declarations have been made. Adam S. Luring reports
565 consultant fees from Sanofi and fees from Roche for membership on a trial steering committee. James
566 D. Chappell reports grant support from CDC and NIH. Manjusha Gaglani reports grant support from CDC.
567 Adit A. Ginde reports grant support from CDC, NIH, DOD, and investigator-initiated grant support from
568 AbbVie and Faron Pharmaceuticals. H. Keipp Talbot reports a grant from CDC. Jonathan D. Casey reports
569 a grant (K23HL153584) from the National Institutes of Health (NIH). D. Clark Files reports consultant fees
570 from Cytovale and membership on a Medpace Data Safety Monitoring Board (DSMB). David N. Hager
571 reports a contract from CDC (via subcontract with VUMC) and salary support from Incyte Corporation,
572 EMPACT Precision Medicine, and the Marcus Foundation. Matthew C. Exline reports talks on nutrition in
573 COVID pneumonia at ASPEN conference sponsored by Abbott Labs. Michelle N. Gong reports grant
574 support from CDC, funding from NHLBI, and fees for participating on a DSMB for Regeneron. Ithan D.
575 Peltan reports grants from CDC, NIH, Intermountain Research and Medical Foundation, and Janssen
576 Pharmaceuticals, institutional fees from Asahi Kasei Pharma and from Regeneron. Samuel M. Brown
577 reports grants from CDC, Sedana, Janssen, NIH, and the Department of Defense (DOD); fees from
578 Hamilton for chairing a DSMB; institutional fees from Faron; book royalties from Oxford University and

579 Brigham Young University; and personal fees from New York University for service on a DSMB. Emily T.
580 Martin reports a grant from Merck for unrelated work. Akram Khan reports grants from Gilead, Ely Lilly,
581 United Therapeutics, Johnson & Johnson (Actelion), Liquidia Pharmaceuticals, and 4D Medical. Steven Y.
582 Chang was a speaker for La Jolla Pharmaceuticals and a Consultant for PureTech Health. Jennie H. Kwon
583 reports grant support from NIH/NIAID (1K23 AI137321-01A1). Natasha Halasa reports grants from CDC,
584 Sanofi and Quidel. Carlos G. Grijalva reports consultant fees from Pfizer, Merck, and Sanofi-Pasteur and
585 grants from Campbell Alliance/Syneos Health, CDC, NIH, FDA, AHRQ, and Sanofi. Todd Rice reports grant
586 support from CDC. Christopher J. Lindsell reports grants from CDC, NIH, DoD, and the Marcus
587 Foundation; organizational contract fees from bioMerieux, Endpoint LLC, and Entegriion, Inc.; and a
588 patent issued to Cincinnati Children's Hospital Medical Center for risk stratification in sepsis and septic
589 shock. Wesley H. Self reports grant funding from CDC for this work, grants and consultant fees from
590 Merck outside this work and consultant fees from Aerpio Pharmaceuticals outside this work. No other
591 potential conflicts of interest were disclosed.

592 **Patient Consent:** not applicable.

593 **Ethical Approval:** This program was approved as a public health surveillance activity with waiver of
594 informed consent by institutional review boards at the US Centers for Disease Control and Prevention
595 (CDC), the program's coordinating center at Vanderbilt University Medical Center and each participating
596 site.

597 **Data Sharing:** No additional data are available.

598

599 **REFERENCES**

- 600 1 Luring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2—What Do They Mean? *JAMA*
601 2021;**325**:529. doi:10.1001/jama.2020.27124
- 602 2 Tracking SARS-CoV-2 variants. [https://www.who.int/health-topics/typhoid/tracking-SARS-CoV-2-](https://www.who.int/health-topics/typhoid/tracking-SARS-CoV-2-variants)
603 variants (accessed 26 Oct 2021).
- 604 3 GISAID - hCov19 Variants. <https://www.gisaid.org/hcov19-variants/> (accessed 26 Oct 2021).
- 605 4 Sheikh A, McMenamin J, Taylor B, *et al.* SARS-CoV-2 Delta VOC in Scotland: demographics, risk of
606 hospital admission, and vaccine effectiveness. *The Lancet* 2021;**397**:2461–2. doi:10.1016/S0140-
607 6736(21)01358-1
- 608 5 Twohig KA, Nyberg T, Zaidi A, *et al.* Hospital admission and emergency care attendance risk for
609 SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *The*
610 *Lancet Infectious Diseases* 2022;**22**:35–42. doi:10.1016/S1473-3099(21)00475-8
- 611 6 Taylor CA, Patel K, Pham H, *et al.* Severity of Disease Among Adults Hospitalized with Laboratory-
612 Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance
613 — COVID-NET, 14 States, January–August 2021. *MMWR Morb Mortal Wkly Rep* 2021;**70**:1513–9.
614 doi:10.15585/mmwr.mm7043e1
- 615 7 Viana R, Moyo S, Amoako DG, *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in
616 southern Africa. *Nature* Published Online First: 7 January 2022. doi:10.1038/s41586-022-04411-y
- 617 8 Lewnard JA, Hong VX, Patel MM, *et al.* Clinical outcomes among patients infected with Omicron
618 (B.1.1.529) SARS-CoV-2 variant in southern California. *Epidemiology* 2022.
619 doi:10.1101/2022.01.11.22269045
- 620 9 Collie S, Champion J, Moultrie H, *et al.* Effectiveness of BNT162b2 Vaccine against Omicron Variant
621 in South Africa. *N Engl J Med* 2021;:NEJMc2119270. doi:10.1056/NEJMc2119270
- 622 10 Johnson AG, Amin AB, Ali AR, *et al.* COVID-19 Incidence and Death Rates Among Unvaccinated and
623 Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron
624 Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. *MMWR Morb Mortal Wkly*
625 *Rep* 2022;**71**:132–8. doi:10.15585/mmwr.mm7104e2
- 626 11 Thompson MG, Natarajan K, Irving SA, *et al.* Effectiveness of a Third Dose of mRNA Vaccines Against
627 COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations
628 Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10
629 States, August 2021–January 2022. *MMWR Morb Mortal Wkly Rep* 2022;**71**:139–45.
630 doi:10.15585/mmwr.mm7104e3
- 631 12 Tenforde MW, Self WH, Naioti EA, *et al.* Sustained Effectiveness of Pfizer-BioNTech and Moderna
632 Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July
633 2021. *MMWR Morb Mortal Wkly Rep* 2021;**70**:1156–62. doi:10.15585/mmwr.mm7034e2

- 634 13 Tenforde MW, Self WH, Adams K, *et al.* Association Between mRNA Vaccination and COVID-19
635 Hospitalization and Disease Severity. *JAMA* 2021;**326**:2043. doi:10.1001/jama.2021.19499
- 636 14 Tenforde MW, Patel MM, Ginde AA, *et al.* Effectiveness of Severe Acute Respiratory Syndrome
637 Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in
638 the United States. *Clinical Infectious Diseases* 2021;:ciab687. doi:10.1093/cid/ciab687
- 639 15 Self WH, Tenforde MW, Rhoads JP, *et al.* Comparative Effectiveness of Moderna, Pfizer-BioNTech,
640 and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults
641 Without Immunocompromising Conditions — United States, March–August 2021. *MMWR Morb*
642 *Mortal Wkly Rep* 2021;**70**:1337–43. doi:10.15585/mmwr.mm7038e1
- 643 16 Patel MK, Bergeri I, Bresee JS, *et al.* Evaluation of post-introduction COVID-19 vaccine effectiveness:
644 Summary of interim guidance of the World Health Organization. *Vaccine* 2021;**39**:4013–24.
645 doi:10.1016/j.vaccine.2021.05.099
- 646 17 Lewnard JA, Patel MM, Jewell NP, *et al.* Theoretical Framework for Retrospective Studies of the
647 Effectiveness of SARS-CoV-2 Vaccines. *Epidemiology* 2021;**32**:508–17.
648 doi:10.1097/EDE.0000000000001366
- 649 18 Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine
650 Dose for Certain Immunocompromised Individuals. FDA. 2021.[https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised)
651 [events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised)
652 [certain-immunocompromised](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised) (accessed 31 Jan 2022).
- 653 19 Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-
654 19 Vaccine Boosters. FDA. 2021.[https://www.fda.gov/news-events/press-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters)
655 [announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-covid-19-vaccine-boosters)
656 (accessed 31 Jan 2022).
- 657 20 Tenforde MW, Patel MM, Gaglani M, *et al.* Effectiveness of a Third Dose of Pfizer-BioNTech and
658 Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and
659 Immunocompromised Adults - United States, August-December 2021. *MMWR Morb Mortal Wkly*
660 *Rep* 2022;**71**:118–24. doi:10.15585/mmwr.mm7104a2
- 661 21 US Food and Drug Administration. CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR
662 Diagnostic Panel. 2021.<https://www.fda.gov/media/134922/download> (accessed 26 May 2021).
- 663 22 Quick J. nCoV-2019 sequencing protocol v3 (LoCost). protocols.io.
664 2020.<https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye> (accessed
665 26 May 2021).
- 666 23 Rambaut A, Holmes EC, O’Toole Á, *et al.* A dynamic nomenclature proposal for SARS-CoV-2 lineages
667 to assist genomic epidemiology. *Nat Microbiol* 2020;**5**:1403–7. doi:10.1038/s41564-020-0770-5
- 668 24 Marshall JC, Murthy S, Diaz J, *et al.* A minimal common outcome measure set for COVID-19 clinical
669 research. *The Lancet Infectious Diseases* 2020;**20**:e192–7. doi:10.1016/S1473-3099(20)30483-7

- 670 25 Centers for Disease Control and Prevention. COVID Data Tracker. 2022.<https://covid.cdc.gov/covid->
671 [data-tracker/#datatracker-home](https://covid.cdc.gov/covid-data-tracker/#datatracker-home) (accessed 31 Jan 2022).
- 672 26 Griffith GJ, Morris TT, Tudball MJ, *et al.* Collider bias undermines our understanding of COVID-19
673 disease risk and severity. *Nat Commun* 2020;**11**:5749. doi:10.1038/s41467-020-19478-2
- 674 27 Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study Design
675 for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol* 2016;**184**:345–53.
676 doi:10.1093/aje/kww064
- 677 28 Rufino J, Baquero C, Frey D, *et al.* Using Survey Data to Estimate the Impact of the Omicron Variant
678 on Vaccine Efficacy against COVID-19 Infection. *Public and Global Health* 2022.
679 doi:10.1101/2022.01.21.22269636
- 680 29 Tseng HF, Ackerson BK, Luo Y, *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and
681 delta variants. *Infectious Diseases (except HIV/AIDS)* 2022. doi:10.1101/2022.01.07.22268919
- 682 30 Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against Omicron among Veterans. *Infectious*
683 *Diseases (except HIV/AIDS)* 2022. doi:10.1101/2022.01.15.22269360
- 684

Table 1. Characteristics of patients included in the evaluation of vaccine effectiveness to preventing COVID-19 hospitalizations, including hospitalized patients without COVID-19 (controls) and hospitalized patients with COVID-19 (cases) during the Alpha period (March 11 - July 3, 2021), Delta period (July 4 - December 25, 2021), and Omicron period (December 26, 2021- January 14, 2022). (Baseline characteristics for cases limited to those with a sequencing-confirmed variant are shown in Table S4.)

| Patient Characteristics | All controls (n=5962) | Alpha cases (n=1072) | Delta cases (n=3951) | Omicron cases (n=559) |
|--|--------------------------|-------------------------|-------------------------|--------------------------|
| Age in years, median (IQR) | 63 (50-72) | 56 (43-65.5) | 57 (43-69) | 62 (49-73) |
| Female sex, No. (%) | 2975 (49.9) | 519 (48.4) | 1803 (45.6) | 264 (47.2) |
| Race and ethnicity, No. (%) | | | | |
| Non-Hispanic White | 3611 (60.6) | 484 (45.1) | 2183 (55.3) | 279 (49.9) |
| Non-Hispanic Black | 1240 (20.8) | 285 (26.6) | 820 (20.8) | 127 (22.7) |
| Hispanic, any race | 772 (12.9) | 220 (20.5) | 695 (17.6) | 111 (19.9) |
| Non-Hispanic, Other | 253 (4.2) | 63 (5.9) | 179 (4.5) | 33 (5.9) |
| Unknown | 86 (1.4) | 20 (1.9) | 74 (1.9) | 9 (1.6) |
| US Census region, No. (%) | | | | |
| Northeast | 885 (14.8) | 158 (14.7) | 686 (17.4) | 159 (28.4) |
| South | 2371 (39.8) | 395 (36.8) | 1544 (39.1) | 196 (35.1) |
| Midwest | 1374 (23.0) | 248 (23.1) | 978 (24.8) | 104 (18.6) |
| West | 1332 (22.3) | 271 (25.3) | 743 (18.8) | 100 (17.9) |
| Resident of long-term care facility, No. / Total (%) | 321/5778 (5.6) | 25/1039 (2.4) | 120/3795 (3.2) | 30/534 (5.6) |
| ≥1 prior hospitalization in past year, No. / Total (%) | 3031/5537 (54.7) | 282/956 (29.5) | 1015/3682 (27.6) | 226/535 (42.2) |
| Current tobacco use, No. / Total (%) | 1016/5302 (19.2) | 103/887 (11.6) | 366/3451 (10.6) | 59/470 (12.6) |
| Number of chronic medical conditions‡, median (IQR) | 2 (1-3) | 1 (1-3) | 1 (0-3) | 2 (1-3) |
| Categories of medical conditions‡ | | | | |
| Chronic cardiovascular disease | 4158 (69.7) | 589 (54.9) | 2141 (54.2) | 359 (64.2) |
| Chronic pulmonary disease | 1973 (33.1) | 231 (21.5) | 827 (20.9) | 151 (27.0) |
| Diabetes mellitus | 1962 (32.9) | 316 (29.5) | 1135 (28.7) | 164 (29.3) |
| Immunocompromising condition* | 1458 (24.5) | 172 (16.0) | 659 (16.7) | 138 (24.7) |
| Obesity, No. / Total (%) | 2391/5900 (40.5) | 616/1056 (58.3) | 2099/3909 (53.7) | 260/556 (46.8) |
| Vaccination status | | | | |
| Unvaccinated | 2054 (34.5) | 953 (88.9) | 2871 (72.7) | 268 (47.9) |
| 2 doses (<150 days) | 2029 (34.0) | 119 (11.1) | 352 (8.9) | 34 (6.1) |
| 2 doses (≥150 days) | 1411 (23.7) | 0 (0) | 667 (16.9) | 177 (31.7) |
| 3 doses | 468 (7.8) | 0 (0) | 61 (1.5) | 80 (14.3) |
| If vaccinated, vaccine product received, No. / Total (%) | | | | |
| BNT162b2 (Pfizer-BioNTech) | 2269/3908 (58.1) | 81/119 (68.1) | 708/1080 | 203/291 (69.8) |

| | | | | |
|---|------------------|---------------|-----------------|----------------|
| | | | (65.6) | |
| mRNA-1273 (Moderna) | 1615/3908 (41.3) | 37/119 (31.1) | 368/1080 (34.1) | 84/291 (28.9) |
| Mixed products | 24/3908 (0.6) | 1/119 (0.8) | 4/1080 (0.4) | 4/291 (1.4) |
| Days since dose 3 if 3 doses received, median (IQR) | 41 (23-64) | --- | 38 (23-65) | 69.5 (41.5-97) |

Definitions: IQR = interquartile range; US = United States

*Immunocompromising conditions were obtained using structured medical chart review and defined as 1 or more of the following: active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer, HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant, immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.

Table 2. In-hospital clinical outcomes among adults hospitalized with COVID-19 by variant group (Alpha, Delta, Omicron).

| Outcome | Alpha Group (n=1060) | | | Delta Group (n=3788) | | | Omicron Group (n=565) | | |
|--|----------------------|----------------|--------|----------------------|------------------|--------|-----------------------|---------------|-------|
| | Vaccinated | Unvaccinated | P* | Vaccinated | Unvaccinated | P* | Vaccinated | Unvaccinated | P* |
| Death, no. (%) | 5/116 (4.3) | 76/944 (8.1) | 0.15 | 138/1045 (13.2) | 323/2743 (11.8) | 0.23 | 15/293 (5.1) | 25/272 (9.2) | 0.059 |
| Invasive mechanical ventilation, no. (%) | 7/116 (6.0) | 201/944 (21.3) | <0.001 | 152/1045 (14.5) | 681/2743 (24.8) | <0.001 | 35/293 (11.9) | 49/272 (18.0) | 0.043 |
| Composite of death or invasive mechanical ventilation, no. (%) | 10/116 (8.6) | 218/944 (23.1) | <0.001 | 210/1045 (20.1) | 748/2743 (27.3) | <0.001 | 42/293 (14.3) | 54/272 (19.9) | 0.08 |
| Admitted to intensive care unit, No. (%) | 24/116 (20.7) | 353/944 (37.4) | <0.001 | 321/1045 (30.7) | 1179/2742 (43.0) | <0.001 | 66/293 (22.5) | 89/271 (32.8) | 0.006 |
| Non-invasive ventilation, no. (%) | 15/116 (12.9) | 167/944 (17.7) | 0.20 | 151/1045 (14.4) | 470/2743 (17.1) | 0.046 | 39/293 (13.3) | 43/272 (15.8) | 0.40 |
| High-flow oxygen therapy, no. (%) | 15/116 (12.9) | 324/944 (34.3) | <0.001 | 289/1045 (27.7) | 1148/2743 (41.9) | <0.001 | 59/293 (20.1) | 84/272 (30.9) | 0.003 |
| Vasopressors, no. (%) | 5/116 (4.3) | 191/944 (20.2) | <0.001 | 155/1045 (14.8) | 647/2743 (23.6) | <0.001 | 36/293 (12.3) | 46/272 (16.9) | 0.12 |
| New renal replacement therapy, no. (%) | 6/116 (5.1) | 43/944 (4.6) | 0.91 | 49/1045 (4.7) | 159/2743 (5.8) | 0.18 | 14/293 (4.8) | 12/272 (4.4) | 0.84 |
| Hospital length among survivors, median (IQR) | 5 (3-8) | 5 (3-9) | 0.56 | 5 (3-9) | 6 (3-10) | <0.001 | 5 (3-9) | 6 (3-11) | 0.050 |
| Venous thromboembolic event, No. (%) | 7/116 (6.0) | 55/944 (5.8) | 0.93 | 46/1045 (4.4) | 250/2743 (9.1) | <0.001 | 15/293 (5.1) | 22/272 (8.1) | 0.15 |
| Stroke, No. (%) | 0/116 (0) | 18/944 (1.9) | 0.13 | 9/1045 (0.9) | 44/2743 (1.6) | 0.08 | 3/293 (1.0) | 4/272 (1.5) | 0.63 |
| Myocardial infarction, No. (%) | 1/116 (0.9) | 19/944 (2.0) | 0.39 | 29/1045 (2.8) | 58/2743 (2.1) | 0.23 | 5/293 (1.7) | 5/272 (1.8) | 0.91 |

* P-values obtained using chi-square testing, not adjusting for other factors.

Figure 1. Sequenced SARS-CoV-2 variants by week among patients with COVID-19 enrolled in this study and hospitalized between March 11, 2021 and January 14, 2022 in 21 hospitals in the United States. Vertical dashed lines at July 4, 2021 and December 25, 2021 represent the start of the Delta period and Omicron period, respectively. This figure includes all cases enrolled in the program with a sequencing result, without restriction to cases included in the vaccine effectiveness analyses. SARS-CoV-2 variant lineages were identified for 3017 cases, including alpha (299), beta (8), delta (2209), gamma (52), omicron (286), and lineage not designated as variant of concern (163).




Figure 2. Vaccine effectiveness of COVID-19 mRNA vaccines to prevent COVID-19 hospitalizations by variant group, including Alpha, Delta, and Omicron.

| COVID-19 Hospitalizations | | | | |
|---|------------------------------------|---------------------------------------|----------------------------|---|
| Group | No. vaccinated/ Total cases (%) | No. vaccinated/ Total controls (%) | Adjusted VE, % (95% CI) | |
| Alpha period (March 11 – July 3, 2021) – 2 doses | | | | |
| Overall | 119/1072 (11.0) | 893/1738 (51.4) | 85 (82-88) | ■ |
| By immunocompromised status‡ | | | | |
| Yes | 49/172 (28.5) | 218/398 (54.8) | 58 (33-73) | ■ |
| No | 70/900 (7.8) | 675/1340 (50.4) | 90 (87-93) | ■ |
| By age group | | | | |
| 18-64 | 46/779 (5.9) | 357/985 (36.2) | 87 (82-91) | ■ |
| ≥65 | 73/293 (24.9) | 536/753 (71.2) | 85 (80-89) | ■ |
| By chronic medical conditions§ | | | | |
| 0 chronic conditions | 4/262 (1.5) | 65/208 (31.3) | 96 (89-99) | ■ |
| ≥1 chronic condition | 115/810 (14.2) | 828/1530 (54.1) | 83 (79-87) | ■ |
| By mRNA vaccine product | | | | |
| BNT162b2 (Pfizer-BioNTech) | 81/1034 (7.8) | 519/1364 (38.0) | 82 (77-86) | ■ |
| mRNA-1273 (Moderna) | 37/990 (3.7) | 374/1219 (30.7) | 90 (85-93) | ■ |
| Delta period (July 4- December 25, 2021) – 2 doses | | | | |
| Overall | 1019/3890 (26.2) | 2389/3509 (68.1) | 85 (83-87) | ■ |
| 2 doses (≤150 days) | 352/3223 (10.9) | 1103/2223 (49.6) | 88 (86-90) | ■ |
| 2 doses (>150 days) | 667/3538 (18.9) | 1286/2406 (53.4) | 81 (78-84) | ■ |
| By immunocompromised status‡ | | | | |
| Yes | 329/614 (53.6) | 570/780 (73.1) | 63 (52-71) | ■ |
| No | 690/3276 (21.1) | 1819/2729 (66.7) | 88 (86-90) | ■ |
| By age group | | | | |
| 18-64 | 427/2586 (16.5) | 1152/1957 (58.9) | 88 (86-89) | ■ |
| ≥65 | 592/1304 (45.4) | 1237/1552 (79.7) | 81 (77-84) | ■ |
| By chronic medical conditions§ | | | | |
| 0 chronic conditions | 63/1057 (6.0) | 210/364 (57.7) | 96 (95-98) | ■ |
| ≥1 chronic condition | 956/2833 (33.7) | 2179/3145 (69.3) | 80 (78-82) | ■ |
| By mRNA vaccine product | | | | |
| BNT162b2 (Pfizer-BioNTech) | 668/3539 (18.9) | 1353/2473 (54.7) | 82 (80-84) | ■ |
| mRNA-1273 (Moderna) | 347/3218 (10.8) | 1033/2153 (48.0) | 88 (86-90) | ■ |
| Delta period (July 4- December 25, 2021) – 3 doses | | | | |
| Overall | 61/2932 (2.1) | 333/1453 (22.9) | 94 (92-95) | ■ |
| Immunocompromised | 45/330 (13.6) | 165/375 (44.0) | 87 (78-92) | ■ |
| Immunocompetent | 16/2602 (0.6) | 168/1078 (15.6) | 97 (95-98) | ■ |
| Omicron period (December 26- January 14, 2022) – 2 doses | | | | |
| Overall | 211/479 (44.1) | 158/247 (64.0) | 65 (51-75) | ■ |
| Immunocompetent only | 156/382 (40.8) | 116/191 (60.7) | 66 (49-77) | ■ |
| Omicron period (December 26- January 14, 2022) – 3 doses | | | | |
| Overall | 80/348 (23.0) | 135/224 (60.3) | 86 (77-91) | ■ |
| Immunocompetent only | 39/265 (14.7) | 76/151 (50.3) | 86 (75-92) | ■ |

Definitions: VE = vaccine effectiveness


‡ Immunocompromising conditions were obtained using structured medical chart review and defined as 1 or more of the following: active solid organ cancer (active cancer defined as treatment for the cancer or newly diagnosed cancer in the past 6 months), active hematologic cancer, HIV infection without AIDS, AIDS, congenital immunodeficiency syndrome, previous splenectomy, previous solid organ transplant,

immunosuppressive medication, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, scleroderma, or inflammatory bowel disease, including Crohn's disease or ulcerative colitis.

§ Chronic medical conditions were obtained using structured medical chart review and defined as conditions within 1 or more of the following categories: cardiovascular disease, neurologic disease, pulmonary disease, gastrointestinal disease, endocrine disease, renal disease, hematologic disease, malignancy, immunosuppression not captured in other categories, autoimmune condition, or other condition (sarcoidosis, amyloidosis, or unintentional weight loss ≥ 10 pounds (4.5 kg) in the last 90 days).

Figure 3. COVID-19 disease severity during index hospitalization among adults hospitalized with COVID-19, by SARS-CoV-2 variant for (A) unvaccinated patients, and (B) vaccinated patients. Disease severity was classified based on the highest severity level reached on the World Health Organization Clinical Progression Scale, which ranged from hospitalized without oxygen therapy (lowest level) to death (highest level). Among unvaccinated patients, severity was higher for Delta than Alpha (aPOR: 1.28, 95% CI: 1.11 to 1.46), lower for Omicron than Delta (aPOR: 0.61, 95% CI: 0.49 to 0.77). For each variant, severity was lower for vaccinated patients (2 or 3 doses of an mRNA vaccine) than unvaccinated patients, including for Alpha (aPOR: 0.33, 95% CI: 0.23 to 0.49), Delta (aPOR: 0.44, 95% CI: 0.37 to 0.51), and Omicron (aPOR: 0.61, 95% CI: 0.44 to 0.85). Data represented in the figures are shown in the accompanying table.

A) Unvaccinated COVID-19 cases



B) Vaccinated COVID-19 cases





Figure 3 accompanying data table

| Severity Category, no. (%) | Alpha | | Delta | | Omicron | |
|--|----------------------|--------------------|-----------------------|---------------------|----------------------|--------------------|
| | Unvaccinated (n=944) | Vaccinated (n=116) | Unvaccinated (n=2743) | Vaccinated (n=1045) | Unvaccinated (n=272) | Vaccinated (n=293) |
| In-hospital death | 76 (8.1) | 5 (4.3) | 323 (11.8) | 138 (13.2) | 25 (9.2) | 15 (5.1) |
| Hospitalized with IMV plus other organ support | 119 (12.6) | 4 (3.4) | 360 (13.1) | 54 (5.2) | 24 (8.8) | 22 (7.5) |
| Hospitalized with IMV | 23 (2.4) | 1 (0.9) | 65 (2.4) | 18 (1.7) | 5 (1.8) | 5 (1.7) |
| Hospitalized with NIV or HFNC | 193 (20.4) | 20 (17.2) | 624 (22.7) | 161 (15.4) | 57 (21.0) | 45 (15.4) |
| Hospitalized with low flow O2 | 382 (40.5) | 51 (44.0) | 1017 (37.1) | 409 (39.1) | 102 (37.5) | 129 (44.0) |
| Hospitalized without O2 | 151 (16.0) | 35 (30.2) | 354 (12.9) | 265 (25.4) | 59 (21.7) | 77 (26.3) |

Definitions: HFNC = high-flow nasal cannula; IMV = invasive mechanical ventilation; O2 = oxygen; NIV = non-invasive ventilation

Figure 4. Vaccine effectiveness of two or three doses of COVID-19 mRNA vaccines among adults hospitalized with COVID-19 to prevent disease progression to invasive mechanical ventilation or death, by SARS-CoV-2 variant.



Definitions: IMV = invasive mechanical ventilation; VE = vaccine effectiveness